{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
l-glutamine
to a specific field?
Status:
Investigational
Source:
NCT01348919: Phase 1/Phase 2 Interventional Completed Multiple Myeloma
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Delanzomib (CEP-18770), a proteasome inhibitor, was being developed by Cepahlon (a subsidiary of Teva) for the treatment of cancer and immunological disorders. Delanzomib (CEP-18770) induces apoptotic cell death in multiple myeloma (MM) cell lines and in primary purified CD138-positive explant cultures from untreated and bortezomib-treated MM patients. In vitro, Delanzomib (CEP-18770) has a strong antiangiogenic activity and potently represses RANKL-induced osteoclastogenesis. Delanzomib represses the proteasomal degradation of a variety of proteins, including inhibitory kappaBalpha (IkappaBalpha), resulting in the cytoplasmic sequestration of the transcription factor NF-kappaB; inhibition of NF-kappaB nuclear translocation and transcriptional up-regulation of a variety of cell growth-promoting factors; and apoptotic cell death in susceptible tumor cell populations. In vitro studies indicate that this agent exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors, and bone marrow-derived stromal cells relative to the proteasome inhibitor bortezomib. Delanzomib has been in phase II clinical trials for the treatment of multiple myeloma (MM). However, this research has been discontinued. Currently Delanzomib is on Phase I clinical trial for Non-Hodgkin's lymphoma and Solid tumours.
Status:
Investigational
Source:
JAN:MOVELTIPRIL CALCIUM [JAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Moveltipril is a captopril derivative patented by Japanese pharmaceutical company Chugai Pharmaceutical Co., Ltd. as an angiotensin-converting enzyme inhibitor, that decreases systemic blood pressure more slowly and persistently than captopril. Moveltipril is partially metabolized to captopril by hydrolysis, predominantly in the liver. In preclinical studies administration of Moveltipril to the anesthetized dogs produced a gradual and dose-dependent decline in aortic pressure associated with no marked changes in coronary blood flow, heart rate. Both Moveltipril and captopril inhibited selectively the pressor response to angiotensin I in a dose-related manner.
Status:
Investigational
Source:
NCT00884520: Early Phase 1 Interventional Completed Lung Cancer
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
JAN:L-TYROSINE ETHYLESTER MONOHYDROCHLORIDE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Tyrosine ethyl ester hydrochloride is used as a medical and organic intermediate and as an important amino protective agent. It is also used to introduce t-Boc protect gene. Tyrosine ethyl ester hydrochloride is used as a supplement (tyrosine).
Status:
Investigational
Source:
NCT03388749: Phase 1/Phase 2 Interventional Completed Leukemia, Myeloid, Acute
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Annamycin is a highly lipophilic form of the anthracycline doxorubicin with the ability to bypass multidrug resistance mechanisms of cellular drug resistance. Annamycin belongs to the anthracycline class of drugs, and has a pleiotropic mechanism of action where it targets topoisomerase II, causing strand breaks in DNA. Annamycin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. The agent is being evaluated in separate phase 1 and phase 2 trials in the United States and Europe. Studies in animal models showed the agent to be noncardiotoxic. Trials that included patients with leukemia showed the agent was associated with fewer dose-limiting toxicities than typically experienced with doxorubicin. The FDA granted fast track designation to Annamycin for treatment of patients with relapsed or refractory acute myeloid leukemia.
Status:
Investigational
Source:
NCT04346693: Phase 3 Interventional Completed Acute Respiratory Tract Infection
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00845169: Not Applicable Interventional Completed Endothelial Dysfunction
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT02891785: Not Applicable Interventional Completed Cancer Pain Self-management
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01193491: Phase 1 Interventional Terminated Hematologic Malignancies
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
IPI-493 (17-AG, 17-Aminogeldanamycin) is the major metabolite of tanespimycin (17-AAG) and retaspimycin (17-DMAG) with potent antineoplastic activity. Hsp90 controls the proper folding, function, and stability of various "client" proteins within cells. Many of the clients of Hsp90 (such as Akt, Bcr-Abl, EGFR, Flt-3, c-Kit and PDGFR α) are oncoproteins or important cell-signaling proteins, and therefore are critical for tumor cell growth and survival. Inhibition of Hsp90 results in degradation of these proteins, which abrogates growth and survival signaling and leads to tumor cell death. IPI-493 has been used in trials studying the treatment of Advanced Malignancies.
Status:
Investigational
Source:
NCT01854294: Phase 2 Interventional Completed Amyotrophic Lateral Sclerosis
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
GM-602 (GM6) is a six-amino-acid active analog peptide of Motoneuronotrophic factor (MNTF). This compound is a small peptide that can cross the blood-brain barrier and has been shown to induce an embryonic-like neuroprotective microenvironment that helps detect and self-correct CNS- and neurodegenerative-related pathophysiology. Phase II clinical trials with GM-602, GM-604 and GM-608 have been completed to examine its potential in respectively stroke, Amyotrophic Lateral Sclerosis (ALS), and Parkinson’s disease.
